Novel markers of nephrotoxicity, including kidney injury molecule 1 (KIM-1), interleukin 18 (IL-18), and beta-2 microglobulin, were used in the detection of acute renal injury. The aim of the study was to establish the frequency of postchemotherapy chronic kidney dysfunction in children and to assess the efficacy of IL-18, KIM-1, and beta-2 microglobulin in the detection of chronic nephropathy. We examined eighty-five patients after chemotherapy (median age of twelve years). The median age at the point of diagnosis was 4.2 years, and the median follow-up time was 4.6 years. We performed classic laboratory tests assessing kidney function and compared the results with novel markers (KIM-1, beta-2 microglobulin, and IL-18). Features of subclinical renal injury were identified in forty-eight children (56.3% of the examined group). Nephropathy, especially tubulopathy, appeared more frequently in patients treated with ifosfamide, cisplatin, and/or carboplatin, following nephrectomy or abdominal radiotherapy ( , , and , resp.). Concentrations of IL-18 and beta-2 microglobulin were comparable with classic signs of tubulopathy ( and ). Concentrations of IL-18 were also significantly higher in children treated with highly nephrotoxic drugs ( ) following nephrectomy ( ) and abdominal radiotherapy ( ). Concentrations of beta-2 microglobulin were higher after highly toxic chemotherapy ( ) and after radiotherapy ( ). ROC curves created utilizing IL-18 data allowed us to distinguish between children with nephropathy (value 28.8?pg/mL) and tubulopathy (37.1?pg/mL). Beta-2 microglobulin and IL-18 seem to be promising markers of chronic renal injury in children after chemotherapy. 1. Introduction Significantly improved results of anticancer treatment in children have led to an increased number of survivors. However, available data show that up to 40% of these children suffer from serious late complications, including heart failure, neurotoxicity, nephrotoxicity, growth impairment, hormonal disorders, and secondary cancers [1]. Late complications not only seriously impair the patients’ quality of life and cause higher rates of hospitalization, but in 15% of cases, they become the direct cause of the patient’s death [2, 3]. Therefore current studies focus on the problems of early diagnosis in the asymptomatic period of the disease, which can result in an order of prophylactic or therapeutic procedures to prevent the progression of late complications. The impairment of renal function after chemotherapy is a field of interest to many international study groups. According to
References
[1]
M. M. Geenen, M. C. Cardous-Ubbink, L. C. M. Kremer et al., “Medical assessment of adverse health outcomes in long-term survivors of childhood cancer,” Journal of the American Medical Association, vol. 297, no. 24, pp. 2705–2715, 2007.
[2]
D. A. Mulrooney, D. C. Dover, S. Li, et al., “Twenty years of follow-up among survivors of childhood and young adult acute myeloid leukemia: a report from the Childhood Cancer Survivor Study,” Cancer, vol. 112, no. 9, pp. 2071–2079, 2008.
[3]
B. A. Kurt, V. G. Nolan, K. K. Ness et al., “Hospitalization rates among survivors of childhood cancer in the childhood cancer survivor study cohort,” Pediatric Blood & Cancer, vol. 59, no. 1, pp. 126–132, 2012.
[4]
B. S. Lee, J. H. Lee, H. G. Kang et al., “Ifosfamide nephrotoxicity in pediatric cancer patients,” Pediatric Nephrology, vol. 16, no. 10, pp. 796–799, 2001.
[5]
R. Rossi, J. Pleyer, P. Sch?fers et al., “Developement of ifosfamide-induced nephrotoxicity: prospective follow-up in 75 patients,” Medical and Pediatric Oncology, vol. 32, no. 3, pp. 177–182, 1999.
[6]
R. Skinner, I. M. Sharkey, A. D. J. Pearson, and A. W. Craft, “Ifosfamide, mesna, and nephrotoxicity in children,” Journal of Clinical Oncology, vol. 11, no. 1, pp. 173–190, 1993.
[7]
R. Skinner, S. J. Cotterill, and M. C. G. Stevens, “Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study,” British Journal of Cancer, vol. 82, no. 10, pp. 1636–1645, 2000.
[8]
R. Skinner, A. D. J. Pearson, M. W. English et al., “Risk factors for ifosfamide nephrotoxicity in children,” The Lancet, vol. 348, no. 9027, pp. 578–580, 1996.
[9]
R. Skinner, A. D. J. Pearson, L. Price, K. Cunningham, and A. W. Craft, “Hypophosphataemic rickets after ifosfamide treatment in children,” British Medical Journal, vol. 298, no. 6687, pp. 1560–1561, 1989.
[10]
S. L. Knijnenburg, M. W. Jaspers, H. J. van der Pal et al., “Renal dysfunction and elevated blood pressure in long-term childhood cancer survivors,” Clinical Journal of the American Society of Nephrology, vol. 7, no. 9, pp. 1416–1427, 2012.
[11]
R. Skinner, A. Parry, L. Price, M. Cole, A. W. Craft, and A. D. J. Pearson, “Glomerular toxicity persists 10 years after ifosfamide treatment in childhood and is not predictable by age or dose,” Pediatric Blood and Cancer, vol. 54, no. 7, pp. 983–989, 2010.
[12]
O. Oberlin, O. Fawaz, A. Rey et al., “Long-term evaluation of ifosfamide-related nephrotoxicity in children,” Journal of Clinical Oncology, vol. 27, no. 32, pp. 5350–5355, 2009.
[13]
R. Skinner, A. Parry, L. Price, M. Cole, A. W. Craft, and A. D. J. Pearson, “Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors,” European Journal of Cancer, vol. 45, no. 18, pp. 3213–3219, 2009.
[14]
K. K. Washburn, M. Zappitelli, A. A. Arikan et al., “Urinary interleukin-18 is an acute kidney injury biomarker in critically ill children,” Nephrology Dialysis Transplantation, vol. 23, no. 2, pp. 566–572, 2008.
[15]
M. H. Rosner, “Urinary biomarkers for the detection of renal injury,” Advances in Clinical Chemistry, vol. 49, pp. 73–97, 2009.
[16]
E. Ho, A. Fard, and A. Maisel, “Evolving use of biomarkers for kidney injury in acute care settings,” Current Opinion in Critical Care, vol. 16, no. 5, pp. 399–407, 2010.
[17]
X. L. Liang, S. X. Liu, Y. H. Chen et al., “Combination of urinary kidney injury molecule-1 and interleukin-18 as early biomarker for the diagnosis and progressive assessment of acute kidney injury following cardiopulmonary bypass surgery: a prospective nested casecontrol study,” Biomarkers, vol. 15, no. 4, pp. 332–339, 2010.
[18]
J. L. Koyner, V. S. Vaidya, M. R. Bennet et al., “Urinary biomarkers in the clinical prognosis and early detection of acute kidney injury,” Clinical Journal of the American Society of Nephrology, vol. 5, no. 12, pp. 2154–2165, 2010.
[19]
C. R. Parikh, J. C. Lu, S. G. Coca, and P. Devarajan, “Tubular proteinuria in acute kidney injury: a critical evaluation of current status and future promise,” Annals of Clinical Biochemistry, vol. 47, no. 4, pp. 301–312, 2010.
[20]
B. C. Widemann, F. M. Balis, A. Kim et al., “Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome,” Journal of Clinical Oncology, vol. 28, no. 25, pp. 3979–3986, 2010.
[21]
M. Darmon, I. Guichard, F. Vincent, B. Schlemmer, and L. Azoulay, “Prognostic significance of acute renal injury in acute tumor lysis syndrome,” Leukemia and Lymphoma, vol. 51, no. 2, pp. 221–227, 2010.
[22]
K. A. Janeway and H. E. Grier, “Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects,” The Lancet Oncology, vol. 11, no. 7, pp. 670–678, 2010.
[23]
M. S. Ashraf, J. Brady, F. Breatnach, P. F. Deasy, and A. O'Meara, “Ifosfamide nephrotoxicity in paediatric cancer patients,” European Journal of Pediatrics, vol. 153, no. 2, pp. 90–94, 1994.
[24]
E. Zielińska, M. Zubowska, and K. Misiura, “Role of GSTM1, GSTP1, and GSTT1 gene polymorphism in ifosfamide metabolism affecting neurotoxicity and nephrotoxicity in children,” Journal of Pediatric Hematology/Oncology, vol. 27, no. 11, pp. 582–589, 2005.
[25]
W. St?hr, M. Paulides, S. Bielack et al., “Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: a report from the late effects surveillance system,” Pediatric Blood and Cancer, vol. 48, no. 4, pp. 447–452, 2007.
[26]
R. Skinner, “Chronic ifosfamide nephrotoxicity in children,” Medical and Pediatric Oncology, vol. 41, no. 3, pp. 190–197, 2003.
[27]
N. M. Marina, C. A. Poquette, A. M. Cain, D. Jones, C. B. Pratt, and W. H. Meyer, “Comparative renal tubular toxicity of chemotherapy regimens including ifosfamide in patients with newly diagnosed sarcomas,” Journal of Pediatric Hematology/Oncology, vol. 22, no. 2, pp. 112–118, 2000.
[28]
K. Arjmandi-Rafsanjani, N. Hooman, and P. Vosoug, “Renal function in late survivors of Iranian children with cancer: single centre experience,” Indian Journal of Cancer, vol. 45, no. 4, pp. 154–157, 2008.
[29]
S. Camano, A. Lazaro, E. Moreno-Gordaliza et al., “Cilastatin attenuates cisplatin-induced proximal tubular cell damage,” Journal of Pharmacology and Experimental Therapeutics, vol. 334, no. 2, pp. 419–429, 2010.
[30]
E. Moore, R. Bellomo, and A. Nichol, “Biomarkers of acute kidney injury in anesthesia, intensive care and major surgery: from the bench to clinical research to clinical practice,” Minerva Anestesiologica, vol. 76, no. 6, pp. 425–440, 2010.
[31]
M. Che, B. Xie, S. Xue et al., “Clinical usefulness of novel biomarkers for the detection of acute kidney injury following elective cardiac surgery,” Nephron Clinical Practice, vol. 115, no. 1, pp. c66–c72, 2010.
[32]
R. Oberbauer, “Biomarkers—a potential route for improved diagnosis and management of ongoing renal damage,” Transplantation Proceedings, vol. 40, no. 10, pp. S44–S47, 2008.
[33]
P. Devarajan, “The future of pediatric acute kidney injury management-biomarkers,” Seminars in Nephrology, vol. 28, no. 5, pp. 493–498, 2008.
[34]
R. J. Trof, F. Di Maggio, J. Leemreis, and A. B. J. Groeneveld, “Biomarkers of acute renal injury and renal failure,” Shock, vol. 26, no. 3, pp. 245–253, 2006.
[35]
E. D. Siew, T. A. Ikizler, T. Gebretsadik et al., “Elevated urinary IL-18 levels at the time of ICU admission predict adverse clinical outcomes,” Clinical Journal of the American Society of Nephrology, vol. 5, no. 8, pp. 1497–1505, 2010.
[36]
H. Wu, M. L. Craft, P. Wang et al., “IL-18 contributes to renal damage after ischemia-reperfusion,” Journal of the American Society of Nephrology, vol. 19, no. 12, pp. 2331–2341, 2008.
[37]
C. L. Edelstein, “Biomarkers of acute kidney injury,” Advances in Chronic Kidney Disease, vol. 15, no. 3, pp. 222–234, 2008.